Abstract
We studied wild-type FLT3 mRNA expression at diagnosis in bone marrow samples from 85 patients with acute myeloid leukemia (AML), 23 of whom were in complete remission, and determined its utility as a marker for minimal residual disease (MRD). We conclude that FLT3 expression is of limited value as a prognostic marker and for MRD monitoring.
Publication types
-
Evaluation Study
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / analysis*
-
Biomarkers, Tumor / genetics
-
Bone Marrow / chemistry*
-
Combined Modality Therapy
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Leukemia, Myeloid / drug therapy
-
Leukemia, Myeloid / genetics
-
Leukemia, Myeloid / mortality
-
Leukemia, Myeloid / pathology*
-
Leukemia, Myeloid / surgery
-
Male
-
Middle Aged
-
Neoplasm Proteins / genetics*
-
Neoplasm, Residual
-
Prognosis
-
RNA, Messenger / analysis*
-
RNA, Messenger / biosynthesis
-
RNA, Neoplasm / analysis*
-
RNA, Neoplasm / biosynthesis
-
Remission Induction
-
Survival Analysis
-
Tretinoin / therapeutic use
-
fms-Like Tyrosine Kinase 3 / genetics*
Substances
-
Biomarkers, Tumor
-
Neoplasm Proteins
-
RNA, Messenger
-
RNA, Neoplasm
-
Cytarabine
-
Tretinoin
-
Etoposide
-
fms-Like Tyrosine Kinase 3
-
Daunorubicin